20
Participants
Start Date
February 1, 2017
Primary Completion Date
March 1, 2020
Study Completion Date
March 1, 2020
Denosumab
Participants will be randomized (1:1) allocation to denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + ULT standard of care OR ULT standard of care therapy
University of Alabama at Birmingham, Birmingham
University of Auckland, New Zealand
OTHER
University of Alabama at Birmingham
OTHER